Litigation

Celgene Corp. v. Amneal Pharmaceuticals

consent judgment

2:24-cv-00500

Auto-generating section 1 of 4: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Terminated
2024-02-05

Patents at issue (2)

7855217
7465800

Plaintiffs (1)

Summary

Celgene sued Amneal Pharmaceuticals in D.N.J. (2:24-cv-00500). The patents-in-suit were U.S. 7,465,800 and 7,855,217, and a consent judgment was entered on February 5, 2024, with a permanent injunction barring Amneal's ANDA No. 216213 until expiration.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).